Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2015
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 15 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned primary completion date changed to 1 Mar 2015 as reported by ClinicalTrials.gov record.